Predictive biomarkers of sustained treatment-free remission in chronic myeloid leukemia: gene expression analyses from the ENESTfreedom and ENESTop studies
Jerald P. Radich, Shalini Chaturvedi, Islam Sadek, Vanessa Obourn
0 citationsHaematologica
Islam Sadek
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
67Publications signalées
257Citations signalées
0Affiliations récentes
Domaines associés
Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia ResearchAcute Myeloid Leukemia ResearchMyeloproliferative Neoplasms: Diagnosis and TreatmentLung Cancer Treatments and Mutations
Publications récentes
Asciminib (ASC) in chronic myeloid leukemia in chronic Phase (CML-CP): Efficacy and safety results of the Phase 2 ASC2ESCALATE trial in the cohort of patients (pts) with 1 prior tyrosine kinase inhibitor (TKI)
Jörge E. Cortes, Ehab Atallah, David Andorsky, Marlise R. Luskin et autres
0 citationsBlood
Asciminib (ASC) in chronic myeloid leukemia in chronic Phase (CML-CP): Interim analysis (IA) efficacy and safety results of the Phase 2 ASC2ESCALATE trial in the cohort of newly diagnosed (1L) patients (pts)
Moshe Levy, David Andorsky, CelesteAnn Bremer, Joshua F. Zeidner et autres
0 citationsBlood
Treatment with asciminib after a prior tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia
Ehab Atallah, Islam Sadek, David Wei, Dominick Latrémouille-Viau et autres
2 citationsLeukemia Research
POSTER: CML-1030 Quality of Life and Work Impacts Among Caregivers of Patients With Chronic Myeloid Leukemia: A Caregiver Survey in the US
Kathryn E. Flynn, Joan Clements, Karen DeMairo, Jennifer Hiller et autres
0 citationsClinical Lymphoma Myeloma & Leukemia
POSTER: ALL-716 Treatment Patterns of Asciminib in Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL): A Retrospective Cohort Analysis
Marlise R. Luskin, Andrea Damon, Islam Sadek, Dominick Latrémouille-Viau et autres
0 citationsClinical Lymphoma Myeloma & Leukemia
POSTER: CML-969 Impact of Adverse Events (AEs) on Health-Related Quality of Life (HRQOL) in Chronic Myeloid Leukemia (CML): Results From the Patient Survey on Humanistic Burden of Intolerance to First or Second Tyrosine Kinase Inhibitors (TKIs) SHIFT Study in the US
Kelly L. Schoenbeck, Joan Clements, Karen DeMairo, Jennifer Hiller et autres
0 citationsClinical Lymphoma Myeloma & Leukemia
CML-969: Impact of Adverse Events (AEs) on Health-Related Quality of Life (HRQOL) in Chronic Myeloid Leukemia (CML): Results From the Patient Survey on Humanistic Burden of Intolerance to First or Second Tyrosine Kinase Inhibitors (TKIs) SHIFT Study in the US
Kelly L. Schoenbeck, Joan Clements, Karen DeMairo, Jennifer Hiller et autres
0 citationsClinical Lymphoma Myeloma & Leukemia
ALL-716: Treatment Patterns of Asciminib in Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL): A Retrospective Cohort Analysis
Marlise R. Luskin, Andrea Damon, Islam Sadek, Dominick Latrémouille-Viau et autres
0 citationsClinical Lymphoma Myeloma & Leukemia
CML-1030: Quality of Life and Work Impacts Among Caregivers of Patients With Chronic Myeloid Leukemia: A Caregiver Survey in the US
Kathryn E. Flynn, Joan Clements, Karen DeMairo, Jennifer Hiller et autres
0 citationsClinical Lymphoma Myeloma & Leukemia
HSR25-182: Patient-Physician Communication About Adverse Events and Impact on Quality of Life to Foster Shared Decision-Making in Chronic Myeloid Leukemia
Kathryn E. Flynn, Joan Clements, Karen DeMairo, Jennifer Hiller et autres
0 citationsJournal of the National Comprehensive Cancer Network
HSR25-174: Impact of Adverse Events on Quality of Life in Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors – Results From the Survey on Humanistic Burden of Intolerance to First or Second TKIs (SHIFT) Study
Kathryn E. Flynn, Joan Clements, Karen DeMairo, Jennifer Hiller et autres
1 citationJournal of the National Comprehensive Cancer Network
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, ROR et la Banque mondiale, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune donnée externe enregistrée en base. Sources et limites.